Association of Leptin Levels With Radiographic Knee Osteoarthritis Among a Cohort of Midlife Women by Karvonen‐gutierrez, Carrie A. et al.
Association of Leptin Levels With Radiographic
Knee Osteoarthritis Among a Cohort of
Midlife Women
CARRIE A. KARVONEN-GUTIERREZ, SIOBA´N D. HARLOW, PETER MANCUSO, JON JACOBSON,
CARLOS F. MENDES DE LEON, AND BIN NAN
Objective. To relate serum leptin levels to prevalent and incident radiographic knee osteoarthritis (OA) and to determine
if patterns of change in longitudinal serum leptin measures differ by knee OA status over a 10-year period.
Methods. Participants in the Michigan Study of Women’s Health Across the Nation underwent bilateral knee radiographs
at baseline and followup visits 2, 4, and 11 for ascertainment of knee OA status (Kellgren/Lawrence score >2). Serum
leptin measures were available from baseline and followup visits 1 and 3–7.
Results. The baseline prevalence of knee OA (mean age 46 years) was 18%; the 2-year incidence of knee OA at followup
visits 2 and 4 was 18% and 14%, respectively. Serum leptin levels were associated with prevalent and incident knee OA.
A 5 ng/ml increase in serum leptin level was associated with 38% higher odds of prevalent knee OA (odds ratio [OR] 1.38,
95% conﬁdence interval [95% CI] 1.26–1.52) and 31% greater odds of incident knee OA (OR 1.31, 95% CI 1.21–1.41) after
adjustment for covariates, including body mass index residuals. Leptin levels increased with time; on average, serum
leptin levels increased by 0.38 ng/ml per year (P  0.0004). Women with incident knee OA during the 10-year followup
period had consistently higher serum leptin levels as compared to women with no knee OA during followup.
Conclusion. Our ﬁndings support a metabolic role of obesity in knee OA. A better understanding of the mechanisms by
which increased fat mass is associated with joint damage is needed. Management of cardiometabolic dysfunction,
including elevated serum leptin levels, may be beneﬁcial in forestalling the onset or progression of knee OA.
INTRODUCTION
As the leading cause of pain, functional limitations, and
disability in the US (1), osteoarthritis (OA) is associated
with decreased productivity and increased health ex-
penditures (2). In 2003, the cost of medical care expendi-
tures and earnings losses associated with arthritis and
rheumatism was an estimated $128 billion (3). OA, a joint
condition characterized by loss of articular cartilage, sub-
chondral bone remodeling, soft tissue damage, and inﬂam-
mation, affects more than 26 million US adults ages 25
years (4).
OA disproportionately afﬂicts women, and the preva-
lence rises dramatically after the menopausal transition
(5,6). However, disagreements persist as to whether the
menopause, the accompanying change in hormone levels,
or some other physiologic processes occurring during
midlife contribute to OA pathogenesis. Support for the
importance of menopause-associated “estrogen deﬁciency”
as a risk factor for knee OA has been mixed (7–11). Better
characterization of the menopause transition has provided
evidence that it is a time of hormonal change but also
dramatic metabolic changes, including decreased energy
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expenditure (12), changes in body composition and topol-
ogy (13,14), and increased risk of metabolic syndrome (15).
Obesity is a well-documented risk factor for knee OA
(16–23), and the impact of obesity on OA onset and pro-
gression is likely due to several mechanisms. Some inves-
tigators have focused on the impact of obesity as a sheer
mechanical force causing increased joint loading and sub-
sequent damage to the articular cartilage (24–26). How-
ever, associations between obesity and OA in non–weight-
bearing joints such as those in the hands and/or wrists
(23,27–29) suggest that additional mechanisms impact
the OA–obesity relationship and emphasize the role of
adipose tissue.
There is emerging evidence about the active metabolic
environment of chondrocytes, including glucose transport,
cholesterol efﬂux, and lipid metabolism (30). These ﬁnd-
ings have prompted the consideration of novel obesity-
related biomarkers in studies of OA, and have suggested
that there may be shared pathophysiology between OA
and cardiovascular and metabolic diseases. Adipose tissue
is now recognized as an endocrine organ, since adipocytes
have the ability to secrete active agents, including adipo-
kines (31). Efforts to examine the adipokines with respect
to OA have focused on leptin because of its strong corre-
lation with body size. Leptin levels in synovial ﬂuid are
correlated with the severity of knee OA (32), and leptin
and its receptor have been identiﬁed in many joint tissues,
including human chondrocytes, osteophytes (33,34), syno-
vium, and infrapatellar fat pad (35).
Leptin might be an important link between obesity and
OA (30,36–39), but epidemiologic evidence of such a re-
lationship is limited, possibly because few studies of OA
have leptin measures available. No studies have evaluated
whether changes in leptin are associated with OA despite
evidence that changes in body size are associated with
joint damage (40,41). Therefore, the goal of this investiga-
tion was to describe the relationship between serum leptin
measures and knee OA prevalence and incidence and to
determine whether changes in serum leptin levels over
time differed by OA status in a middle-aged population of
women.
PATIENTS AND METHODS
The Michigan Study of Women’s Health Across the
Nation (SWAN) is 1 of 7 sites for SWAN, a multiethnic
cohort study characterizing the menopausal transition.
The Michigan SWAN population, established in 1996,
is a population-based sample of women from 2 Detroit-
area communities identiﬁed through a community census
based on electrical utility listings. A total of 543 eligible
women were recruited from the Michigan site, including
325 African American and 218 white women. Eligibility
criteria at baseline included age 42–52 years, having an
intact uterus, having had at least one menstrual period in
the previous 3 months, no use of reproductive hormones
in the previous 3 months, and self-identiﬁcation with the
site’s designated race/ethnic group (either African Ameri-
can or white at the Michigan site).
At baseline (1996), women in the Michigan SWAN com-
pleted the assessment protocol common to all SWAN sites;
then, a supplemental protocol, including radiographs,
was implemented. Women were seen for annual followup
visits, although the supplemental OA protocol was in-
cluded only at baseline and followup visits 2, 4, and 11.
Participation at the annual assessments has been excellent,
with 80% seen at followup visit 11.
Although the number of women participating in the
radiograph protocol varied by year, there were few differ-
ences among those who participated and those who did
not. Race and smoker status varied with annual partici-
pation; at followup visit 2, nonparticipants were more
likely to be African American and current smokers,
whereas at followup visit 4, nonparticipants were more
likely to be white, and at followup visit 11, current smok-
ers were more likely to participate. The University of
Michigan Institutional Review Board approved the study
protocol, and written informed consent was obtained from
each participant.
OA measures. Anteroposterior radiographs of the knees
have been taken with weight bearing in the semiﬂexed
position (42). Radiographs taken at baseline and followup
visits 2 and 4 were obtained using General Electric Medi-
cal Systems radiograph equipment (model X-GE MPX-80).
Radiographs from followup visit 11 were obtained with
the AXIOM Aristos radiographic system with integrated
digital ﬂat detector technology (Siemens). Knees were
scored using the Kellgren/Lawrence (K/L) grading system
of the Atlas of Standard Radiographs of Arthritis (43) such
that 0  normal, 1  doubtful OA, 2  minimal OA, 3 
moderate OA, and 4  severe OA. Participants with arti-
ﬁcial knee replacements were assigned a K/L score of 4.
Prevalent knee OA was deﬁned as at least 1 knee with a
Signiﬁcance & Innovations
● This study is the ﬁrst to examine serum leptin
levels with respect to both prevalent and incident
knee osteoarthritis (OA) and to relate baseline and
longitudinal measures of serum leptin to subse-
quent OA status.
● Serum leptin levels are associated with prevalent
and incident radiographic knee OA in a middle-
aged population of women.
● Serum leptin levels increase with age; on average,
serum leptin levels increased by 0.38 ng/ml per
year (P  0.0004) after adjustment for body mass
index.
● We observed complete separation of estimated
mean serum leptin levels over time among women
with prevalent knee OA at baseline, women with
incident knee OA during the 10-year followup pe-
riod, and women who remained OA free during
followup. Even the lowest estimated mean serum
leptin levels among women with prevalent knee
OA at baseline were higher than the highest esti-
mated levels among women with incident or no
knee OA during followup.
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K/L score 2 at a given visit. Incident knee OA was de-
ﬁned as new knee OA (K/L score 2) in either knee given
that the participant had a K/L score of 0 or 1 in both knees
during the prior data collection cycle.
Leptin assay. The SWAN specimen collection proto-
col includes a fasting blood draw to provide samples
for a specimen repository that is maintained at80°C until
processing. Serum leptin levels were determined spectro-
photometrically using commercially-available colorimet-
ric enzyme immunoassay kits (Millipore) and run accord-
ing to the manufacturer’s instructions. The coefﬁcient of
variation for duplicate samples was 3.7% and the lower
limit of detection was 0.5 ng/ml. Banked serum specimens
from baseline and followup visits 1 and 3–7 were assayed
for leptin.
Other measures. At each annual examination, height
(cm) and weight (kg) were measured using a stadiometer
and a calibrated balance-beam scale, respectively, and
were used to calculate body mass index (BMI). Waist (cm)
and hip (cm) circumferences have been measured annu-
ally using a nonstretchable tape 3 cm above the umbilicus
after a relaxed expiration and the maximum girth around
the buttocks, respectively.
Menopause status was ascertained at each annual ex-
amination based on questions about bleeding patterns,
current hormone use, hysterectomy, and oophorectomy.
Participants were categorized as being premenopausal
(regular menses with bleeding in the past 3 months), early
perimenopausal (bleeding in the past 3 months but in-
creasing irregularity in menses), late perimenopausal
(bleeding in the past year but not in the past 3 months),
postmenopausal (no bleeding for 12 months), hysterectomy,
or unable to determine due to exogenous hormone use.
Race/ethnicity classiﬁcation (African American or white)
and annual current smoker status (yes/no) were deter-
mined by self-report. Age at each visit was calculated as
the visit date minus birth date.
Statistical analysis. Means and SDs or frequencies and
percentages of leptin levels, body size variables, and rele-
vant covariates were examined overall and by knee OA
status. The statistical signiﬁcance of differences by OA
status was evaluated using t-tests, analysis of variance, or
chi-square tests.
To fully utilize the richness of the available data, in-
cluding multiple measures of knee OA status and annual
assessment of serum leptin through followup visit 7, three
analytical approaches were employed to relate serum lep-
tin measures and knee OA status. In the ﬁrst 2 approaches,
the outcome of interest was knee OA, whereas in the third
approach, leptin was the outcome. First, to determine the
association of leptin levels and knee OA prevalence at
baseline, we examined the cross-sectional association of
serum leptin and knee OA using multivariable logistic
regression analysis.
Second, to determine the association of leptin levels
and incident knee OA, discrete time survival analysis
techniques were utilized to model the time to incident
OA at followup visits 2, 4, and 11 as a function of serum
leptin levels. To complete this analysis, a data set was
constructed with multiple observations per participant;
each row in the data set represented a study visit in
which the participant was at risk of knee OA onset through
followup visit 11. Once women developed knee OA, data
from subsequent years of followup were not included in
the data set. The discrete time logistic survival model was
then estimated using logistic regression, whereby the
odds ratios are the effect estimates of interest. The inci-
dence of knee OA at each followup visit was calculated
as the number of new cases of knee OA at a given visit
divided by the number of women who remained at risk for
knee OA. Because serum leptin levels were not available
at followup visits 2 or 11, values from followup visits 1
and 7, respectively, were substituted.
Third, serum leptin levels from baseline to followup
visit 7 were evaluated overall and by prevalent, incident,
or no knee OA status through followup visit 11. Then,
linear mixed models (PROC MIXED) with random inter-
cepts and slopes for age were used to examine level of and
change in serum leptin measures over time. OA status by
time interactions in the model evaluated whether the rates
of change in serum leptin measures differed between
women with prevalent, incident, or no knee OA through
followup visit 11. SAS PROC SGPLOT was used to graph
predicted trajectories of serum leptin measures with cor-
responding 95% conﬁdence intervals (95% CIs) for each
knee OA group.
Due to the collinearity between body size and serum
leptin (r  0.73, P  0.0001), all multivariable modeling
included residuals of BMI as the measure of body size
confounding. The BMI residual variable represents the
variation in BMI that remains following simple regression
of BMI on leptin. Given that serum leptin represents the
metabolic component of body size, the BMI residual rep-
resents the association of body size and OA through other
pathways, including mechanical loading. Interactions of
the BMI residual and serum leptin were tested to assess
potential effect modiﬁcation of the relationship between
leptin and knee OA by body size. A sensitivity analysis
was conducted to examine the consistency of the results
after adjustment for waist to hip ratio instead of the BMI
residuals. When adjusting for waist to hip ratio, the ﬁnd-
ings remained consistent, although the estimates for leptin
were attenuated by 14% (data not shown).
Model ﬁt and ﬁnal model selection were based on
Akaike’s information criterion and chi-square tests com-
paring the log-likelihood ratios between candidate models.
Models were adjusted for age, race/ethnicity, menopause
status (or hysterectomy [yes/no]), smoker status, and BMI
residuals, as appropriate. Statistical signiﬁcance was de-
ﬁned at an alpha level of 0.05 and all analyses were
completed using SAS, version 9.3.
RESULTS
The prevalence of radiographically-deﬁned knee OA in-
creased over the 10-year followup period. At baseline
(mean age 46 years), 18% of participants had knee OA; at
followup visit 11, 66% of women had knee OA (Table 1).
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Similarly, the prevalence of moderate to severe OA (K/L
score 3 or 4) changed from 4% at baseline to 28% ten years
later.
The mean baseline serum leptin level was 30.6 ng/ml.
At followup visit 7, the mean serum leptin level was
38.0 ng/ml (Supplementary Table 1, available in the online
version of this article at http://onlinelibrary.wiley.com/
doi/10.1002/acr.21922/abstract); we observed a statisti-
cally signiﬁcant increasing trend in serum leptin levels
over time (P  0.0001). Serum leptin levels were 43%
higher at baseline among women with knee OA as com-
pared to those without knee OA (P 0.0001). Serum leptin
levels were not different according to race/ethnicity, age,
menopause status, or smoker status.
Fifty-six percent of all participants were obese at base-
line in 1996–1997; by followup visit 11, the prevalence of
obesity increased to 64.6%. Body size measures, with the
exception of height, increased signiﬁcantly over the study
period and were 15–30% greater among women with knee
OA as compared to those without knee OA (Table 2).
By design, 60% of participants were African American
and 40% were white. In accordance with the inclusion
criterion, all participants were premenopausal or early
perimenopausal at baseline and were not taking exoge-
nous hormones. By followup visit 11, most women (78%)
were postmenopausal and only 8% were taking exogenous
hormones. Menopause status differed by OA status at fol-
lowup visit 11 (P  0.01); women with OA were more
likely to have had a hysterectomy as compared to women
without knee OA.
The proportion of women that were current smokers
declined slightly over time; at baseline, 27% of women
were current smokers, whereas 23% were current smokers
at followup visit 11. The proportion of current smokers
was similar among women with and without knee OA at
baseline; however, at followup visit 11, women with knee
OA were less likely to be current smokers as compared to
women without knee OA (19% versus 30%; P  0.01).
Cross-sectional analysis relating leptin levels to preva-
lent knee OA. Baseline serum leptin levels were posi-
tively and signiﬁcantly associated with prevalent knee OA
(Table 3). A 5 ng/ml higher serum leptin level was associ-
ated with 38% greater odds of having knee OA after ad-
justment for age, race/ethnicity, menopause status, current
smoker status, and BMI residuals (95% CI 1.26–1.52).
African American women had 2.6 times greater odds of
having knee OA at baseline as compared to white women
(95% CI 1.46–4.46).
Serum leptin levels and time to incident knee OA. The
2-year incidence of knee OA at followup visits 2 and 4
was 18% and 14%, respectively. At followup visit 11, the
7-year incidence of knee OA was 47%. After adjustment
Table 1. Descriptive characteristics of the Michigan Study of Women’s Health Across the Nation sample at baseline,
followup visit 4, and followup visit 11*
Baseline
(n  542)
Followup visit 4
(n  252)
Followup visit 11
(n  387)
Age, mean  SD years 46.1  2.7 50.2  2.7 56.9  2.8
Weight, mean  SD kg 85.8  21.8 87.9  22.1 90.1  22.2
Height, mean  SD cm 163.5  6.2 162.8  5.8 162.6  6.2
BMI, mean  SD kg/m2 32.1  8.0 33.2  8.3 34.1  8.4
Waist circumference, mean  SD cm 94.1  17.1 98.5  17.6 102.3  17.6
Hip circumference, mean  SD cm 113.9  16.2 115.4  17.0 118.1  16.9
Waist:hip ratio, mean  SD 0.82  0.07 0.85  0.08 0.87  0.08
Leptin level, mean  SD ng/ml 30.6  18.3 34.4  20.1 –
Knee osteoarthritis, no. (%) 98 (18.1) 112 (44.4) 254 (65.6)
K/L score, no. (%)
0 322 (59.4) 61 (24.2) 44 (11.4)
1 122 (22.5) 79 (31.3) 89 (23.0)
2 78 (14.4) 84 (33.3) 147 (38.0)
3 19 (3.5) 27 (10.7) 62 (16.0)
4 1 (0.2) 1 (0.4) 45 (11.6)
Obese (BMI 30 kg/m2), no. (%) 301 (56.1) 153 (61.5) 250 (64.6)
Race/ethnicity, no. (%)
African American 324 (59.8) 181 (71.8) 238 (61.5)
White 218 (40.2) 71 (28.2) 149 (38.5)
Menopause status, no. (%)
Premenopausal 271 (50.3) 11 (4.4) 0 (0.0)
Early perimenopausal 268 (49.7) 104 (41.4) 12 (3.1)
Late perimenopausal 0 (0.0) 37 (14.7) 15 (3.9)
Postmenopausal 0 (0.0) 51 (20.3) 303 (78.3)
Hysterectomy 0 (0.0) 22 (8.8) 52 (13.4)
Unknown, hormone use 0 (0.0) 26 (10.4) 5 (1.3)
Hormone therapy use, no. (%) 0 (0.0) 45 (17.9) 32 (8.3)
Current smoker, no. (%) 146 (27.3) 63 (25.1) 87 (22.5)
* Sample sizes vary slightly for some variables due to data availability. BMI  body mass index; K/L  Kellgren/Lawrence.
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for baseline age, race/ethnicity, baseline smoker status,
and BMI residuals, higher serum leptin levels were asso-
ciated with incident knee OA (Table 4). A 5 ng/ml higher
serum leptin level was associated with 31% greater odds
of incident knee OA (95% CI 1.21–1.41). African American
women had 52% greater odds of incident knee OA (95% CI
1.00–2.30) as compared to white women. Baseline age and
current smoker status were associated with lower odds of
incident knee OA. A 1-year increase in baseline age was
associated with 14% decreased odds of incident knee OA
(95% CI 0.83–0.88). Those who were current smokers had
52% decreased odds of having incident knee OA as com-
pared to those who were not current smokers (95% CI
0.29–0.80).
As a sensitivity analysis, incident knee OA cases were
restricted to only those individuals with a K/L score of 0
at baseline, and ﬁndings were similar. A 5 ng/ml higher
serum leptin level was associated with 30% greater odds
of incident knee OA (95% CI 1.18–1.44) following adjust-
ment for covariates.
Trajectories of leptin in relation to knee OA status
at followup visit 11. Serum leptin levels increased as
women aged; on average, serum leptin levels increased by
0.38 ng/ml per year (P  0.0004). Serum leptin levels were
highest among women with prevalent knee OA at baseline
Table 2. Descriptive characteristics of the Michigan Study of Women’s Health Across the Nation sample at baseline and
followup visit 11 by knee OA status*
Baseline Followup visit 11
No OA OA P No OA OA P
Age, mean  SD years 46.1  2.8 46.0  2.6 0.73 56.6  2.8 57.1  2.8 0.07
Weight, mean  SD kg 82.2  20.0 101.8  22.5  0.0001† 74.9  15.7 98.0  21.0  0.0001†
Height, mean  SD cm 163.5  6.2 163.3  6.4 0.85 162.3  6.5 162.8  6.0 0.48
BMI, mean  SD kg/m2 30.8  7.3 38.1  8.5  0.0001† 28.4  5.9 37.1  7.9  0.0001†
Waist circumference, mean  SD cm 91.5  16.0 105.4  17.5  0.0001† 91.1  15.0 108.1  16.0  0.0001†
Hip circumference, mean  SD cm 111.3  14.9 125.5  17.1  0.0001† 107.1  13.0 123.9  15.8  0.0001†
Waist:hip ratio, mean  SD 0.82  0.07 0.84  0.07 0.02† 0.85  0.08 0.87  0.08 0.003†
Leptin level, mean  SD ng/ml 28.4  17.2 40.6  20.1  0.0001† – –
Obese (BMI 30 kg/m2), no. (%) 221 (50.0) 80 (84.2)  0.0001† 48 (36.1) 202 (79.5)  0.0001†
Ethnicity, no. (%)
African American 249 (56.1) 75 (76.5) 0.0002† 75 (56.4) 163 (64.2) 0.14
White 195 (43.9) 23 (23.5) 58 (43.6) 91 (35.8)
Menopause status, no. (%)
Premenopausal 230 (52.2) 41 (41.8) 0.06 0 (0.0) 0 (0.0) 0.01†
Early perimenopausal 211 (47.9) 57 (58.2) 9 (6.8) 3 (1.2)
Late perimenopausal 0 (0.0) 0 (0.0) 6 (4.5) 9 (3.5)
Postmenopausal 0 (0.0) 0 (0.0) 105 (79.0) 198 (78.0)
Hysterectomy 0 (0.0) 0 (0.0) 12 (9.0) 40 (15.8)
Unknown, hormone use 0 (0.0) 0 (0.0) 1 (0.8) 4 (1.6)
Hormone therapy use, no. (%) 0 (0.0) 0 (0.0) N/A 13 (9.8) 19 (7.5) 0.44
Current smoker, no. (%) 121 (27.8) 25 (25.5) 0.65 40 (30.1) 47 (18.5) 0.01†
* OA  osteoarthritis; BMI  body mass index; N/A  not applicable.
† P  0.05.
Table 3. Cross-sectional analysis of the relationship
between serum leptin values and knee osteoarthritis
status at the baseline visit among the Michigan Study
of Women’s Health Across the Nation participants,
adjusted for age, body mass index residuals,
race/ethnicity, menopause status, and
baseline smoker status
Odds ratio
(95% conﬁdence interval)
Leptin* 1.38 (1.26–1.52)
Age 1.00 (0.92–1.10)
African American vs. white
race/ethnicity
2.55 (1.46–4.46)
Early perimenopausal vs.
premenopausal
1.57 (0.95–2.60)
Current vs. not current smoker 1.05 (0.58–1.90)
* Estimate represents a 5 ng/ml change in leptin value.
Table 4. Discrete survival time analysis of the
relationship between serum leptin values and incident
knee osteoarthritis among the Michigan Study of
Women’s Health Across the Nation participants, baseline
to followup visit 11, adjusted for age, body mass index
residuals, race/ethnicity, and baseline smoker status
Odds ratio
(95% conﬁdence interval)
Leptin* 1.31 (1.21–1.41)
Baseline age 0.86 (0.83–0.88)
African American race/
ethnicity
1.52 (1.00–2.30)
Baseline current vs. not
current smoker
0.48 (0.29–0.80)
* Estimate represents a 5 ng/ml change in leptin value.
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(Figure 1). After adjustment for age, BMI residuals, race/
ethnicity, hysterectomy status, and baseline smoker status,
women with prevalent knee OA at baseline had serum
leptin levels that were 21 ng/ml higher as compared to
women that remained knee OA free throughout the 10
years of followup. Women who developed incident knee
OA during followup had serum leptin levels that were
14 ng/ml higher as compared to those without knee OA.
Most notably, the highest serum leptin levels among
those women who never developed knee OA are still lower
than those among women with knee OA. Also, the serum
leptin levels among those with incident disease during the
followup do not overlap with levels among those with
prevalent disease at baseline. Although serum leptin levels
differed by knee OA status, there was no statistically sig-
niﬁcant difference in the slope of the leptin trajectories
over time among the groups.
To examine whether serum leptin levels were associ-
ated with knee OA progression, the trajectories of leptin
among women with prevalent knee OA at baseline who
progressed to moderate/severe knee OA at followup visit
11 were compared to those among women who did not
progress. Women with prevalent knee OA who progressed
had serum leptin levels that were 3.3 ng/ml higher as
compared to women with prevalent knee OA who did not
progress, but this difference was not statistically signiﬁ-
cant (P  0.35).
DISCUSSION
Although leptin may represent an important link between
obesity and knee OA (30,36–39), few epidemiologic
studies have examined this hypothesis. This study is the
ﬁrst to examine serum leptin levels with respect to prev-
alent and incident knee OA and to relate longitudinal
measures of serum leptin to subsequent OA status in a
large population-based study. In this cohort of midlife
women, higher serum leptin levels were associated with
increased odds of both prevalent and incident knee OA,
but the rate of change in serum leptin levels over time
did not differ by knee OA status. The ﬁnding that serum
leptin levels at baseline were highest among women with
prevalent knee OA as compared to women with 10-year
incident knee OA or no knee OA suggests that these
women are the most metabolically compromised in terms
of high leptin levels. Individuals with prevalent knee OA
at baseline were relatively young at disease onset. We
hypothesize that metabolic dysfunction may be an impor-
tant risk factor for knee OA, particularly among younger
individuals.
Ku et al reported that cross-sectional leptin levels (mea-
sured in synovial ﬂuid) were related to knee OA severity
among a population of knee surgery patients (32). Unlike
our study, however, BMI did not differ by knee OA status,
suggesting that our population and the Ku et al population
differ with respect to body size. Further, the leptin levels
among women in the Michigan SWAN cohort are much
higher than those reported by Ku et al; 74% of the women
in our study had baseline leptin levels that were higher
than the upper range of values reported among the Ku et al
patients (15.8 ng/ml) (32). Data from the Third National
Health and Nutrition Examination Study (NHANES-III)
estimate that the mean serum leptin value among women
ages20 years in the US is 12.7 ng/ml (44), suggesting that
the Ku et al population (32) may have leptin levels lower
than the general US population.
Exploration of the impact of the leptin–OA relationship
among a cohort of women is of particular interest given the
ﬁndings that serum leptin levels were the most important
cardiometabolic biomarker for knee OA among women
using data from NHANES-III (45). Further, differences in
synovial leptin levels among OA patients versus controls
were greater among women as compared to men (32).
Leptin levels are higher among women (46–49) and cor-
relate more strongly with subcutaneous adipose tissue
(46–49), the fat depot that is proportionally larger among
women as compared to men (50). Our data suggest that
leptin may be an important OA biomarker among women.
Mechanistically, leptin has been associated with OA
through catabolic or anabolic mechanisms. Leptin has an
anabolic effect on chondrocytes and osteoblasts (33),
which may be associated with repair of damaged cartilage,
but also increased osteophyte development. Since the K/L
scoring system reﬂects both joint space width (a proxy of
cartilage loss) and the presence of osteophytes, the ana-
bolic impact of leptin with respect to radiographically-
deﬁned knee OA cannot be differentiated. Leptin may also
have a catabolic effect on cartilage due to its proinﬂam-
matory capabilities. Synergistic relationships of leptin
and proinﬂammatory cytokines, including interleukin-1
(IL-1), IL-6, IL-8, matrix metalloproteinase 9 (MMP-9),
MMP-13, and nitric oxide, have been reported (33,51,52).
Increased local inﬂammation within the joint has a cata-
bolic role in cartilage metabolism (51). It is possible that
the proinﬂammatory impact of leptin may be detrimental
to other collagenous tissues within the joint, including the
meniscus and ligaments.
Our analysis was complicated by the fact that leptin,
being a product of adipose tissue, is highly correlated with
all measures of body size, and greater body size is a hy-
pothesized risk factor for knee OA through nonmetabolic
mechanisms such as increased joint loading or poor mus-
cle strength. Therefore, our analyses were adjusted for the
residuals of BMI on leptin in an effort to describe the
Figure 1. Predicted trajectories of serum leptin level (ng/ml)
by knee osteoarthritis (OA) status among the Michigan Study of
Women’s Health Across the Nation (SWAN) participants, ad-
justed for age, body mass index residuals, race/ethnicity, hyster-
ectomy status, and baseline smoker status.
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metabolic impact of obesity (i.e., leptin) on knee OA, over
and above the nonmetabolic effect of greater body size.
Utilization of hand joints may be preferable over knees
as the OA phenotype for studies evaluating the metabolic
impact of obesity on joint status (53). A recent study using
data from NHANES-III found no association of leptin and
hand OA (54). However, in the analysis from Massengale
et al (54), the case deﬁnition of hand OA was based upon
clinical examination in the absence of hand radiographs.
Several studies have documented that radiography is su-
perior to physical examination for the characterization of
hand OA in epidemiologic studies (55–57) and that use
of clinical examination may underestimate the prevalence
of disease. Misclassiﬁcation of OA status in this way may
bias ﬁndings toward the null, which could explain the
study’s report of no association between leptin and hand
OA.
With respect to progression of hand OA, Yusuf et al (58)
reported slightly greater leptin levels (3 ng/ml) among
those with progressive hand OA as compared to nonpro-
gressive disease (P  0.08). The study may have been
underpowered to detect statistically signiﬁcant differences
in leptin levels given the relatively narrow range of leptin
values in this population, which included both men and
women of normal body size. In addition, all participants in
the Yusuf et al cohort had OA in multiple joints, suggest-
ing a more advanced level of disease overall. The mecha-
nism by which leptin is associated with incident OA may
be different than the mechanism by which leptin is asso-
ciated with progressive OA. Taken together, the ﬁndings
with respect to leptin and hand OA are not deﬁnitive and
call for more work to be done exploring leptin levels
among a population including both those with and with-
out radiographic hand OA.
This study examined leptin levels with respect to knee
OA prevalence and incidence in a nonclinical population.
Strengths unique to this study include longitudinal leptin
measures, repeated assessment of knee OA status, and in-
formation about potential confounders, including body
size, menopause status, and smoking. The prevalence of
knee OA continues to increase in the population, likely
because of the aging of the population and the increasing
proliferation of obesity. Although obesity is a known risk
factor for OA, better characterization of the mechanisms
through which greater fat mass is associated with joint
damage will provide important information to aid in pre-
vention and intervention strategies. We have reported here
that serum leptin, an adipokine secreted by adipose tissue,
is associated with knee OA prevalence and incidence over
and above the nonmetabolic impact of BMI. These ﬁndings
provide further evidence that body mass inﬂuences OA
through a metabolic pathway and provides support for the
potential utility of serum leptin as a biomarker for OA risk.
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